* Spectrum Pharmaceuticals Inc SPPI.OQ SPPI.O is expected
to show a rise in quarterly revenue when it reports results on
November 10.
* The Henderson, Nevada-based company is expected to report
revenue of $516.67 thousand, according to the mean estimate from
6 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Spectrum
Pharmaceuticals Inc is for a loss of 28 cents per share. For the
same quarter last year, the company reported a loss of 37 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Spectrum
Pharmaceuticals Inc is $6, about 63.2% above its last closing
price of $2.21.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.25 -0.25 -0.32 Missed -25.5
Mar. 31 2021 -0.30 -0.31 -0.25 Beat 20.6
Dec. 31 2020 -0.29 -0.29 Met 0
Sep. 30 2020 -0.35 -0.35 -0.37 Missed -5.7
Jun. -0.29 -0.32 -0.28 Beat 11.4
30 2020
Mar. 31 2020 -0.34 -0.35 -0.36 Missed -4
Dec. 31 2019 -0.33 -0.33 -0.35 Missed -7.4
Sep. 30 2019 -0.36 -0.41 -0.23 Beat 44.6
This summary was machine generated November 8 at 22:45 GMT. All
figures in US dollars unless otherwise stated